ReCode Therapeutics Announces Closing of Extension to Series B Financing
Retrieved on:
Tuesday, September 19, 2023
Biotechnology, Pharmaceutical, Genetics, Health, Tissue, Central nervous system, Therapy, Doctor of Philosophy, SORT, BLV, MBA, Recode, Cell, Messenger, OUP, Lung, Bayer, Kouki, OrbiMed, Andreessen Horowitz, Investment, Patient, Cystic fibrosis, Drug discovery, Liver, LNP, Primary ciliary dyskinesia, Vaccine, Pharmaceutical industry
ReCode Therapeutics , a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics, today announced the closing of an extension to its Series B financing, raising an additional $50 million, and the appointment of Kouki Harasaki, Ph.D., founding and managing partner of Bioluminescence Ventures (BLV), to the company’s board of directors.
Key Points:
- ReCode Therapeutics , a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics, today announced the closing of an extension to its Series B financing, raising an additional $50 million, and the appointment of Kouki Harasaki, Ph.D., founding and managing partner of Bioluminescence Ventures (BLV), to the company’s board of directors.
- The company recently concluded a final extension to its Series B financing, raising an additional $50 million, for a total of $260 million in funding.
- At BLV, we focus on funding next-generation therapeutics platforms and developing first- and best-in-class programs.
- ReCode, with its cutting-edge genetic medicine platform, is well aligned with our mission,” said Dr. Harasaki.